BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26033427)

  • 1. Survivin siRNA increases sensitivity of primary cultures of ovarian cancer cells to paclitaxel.
    Kar R; Palanichamy JK; Banerjee A; Chattopadhyay P; Jain SK; Singh N
    Clin Transl Oncol; 2015 Sep; 17(9):737-42. PubMed ID: 26033427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
    Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
    Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells.
    Karami H; Baradaran B; Esfahani A; Estiar MA; Naghavi-Behzad M; Sakhinia M; Sakhinia E
    Asian Pac J Cancer Prev; 2013; 14(12):7719-24. PubMed ID: 24460358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of survivin shRNA on chemosensitivity of human ovarian cancer cell line OVCAR3 to paclitaxel].
    Yan XJ; Liang LZ; Zeng ZY; Shi Z; Fu LW
    Ai Zheng; 2006 Apr; 25(4):398-403. PubMed ID: 16613669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Survivin and p53 Expression in Response of Primary Culture of Ovarian Cancer Cells to Treatment With Chemotherapeutic Agents.
    Chawla D; Kar R; Gupta B; Halder S; Garg S; Mehndiratta M; Wadhwa N; Agarwal R
    Int J Gynecol Cancer; 2018 Jul; 28(6):1239-1246. PubMed ID: 29727353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Influence of short hairpin RNA on survivin mRNA expression and chemosensitivity to paclitaxel in ovarian cancer cells].
    Yan XJ; Liang LZ; Zeng ZY; Fu LW; Shi Z
    Zhonghua Fu Chan Ke Za Zhi; 2005 Sep; 40(9):609-13. PubMed ID: 16202317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of JAK2 Reverses Paclitaxel Resistance in Human Ovarian Cancer Cells.
    Xu Y; Zhang J; Wu J; Zhong S; Li H
    Int J Gynecol Cancer; 2015 Nov; 25(9):1557-64. PubMed ID: 26360705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells.
    Dong H; Yao L; Bi W; Wang F; Song W; Lv Y
    J Cancer Res Ther; 2015; 11(4):717-22. PubMed ID: 26881507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
    Chen L; Liang L; Yan X; Liu N; Gong L; Pan S; Lin F; Zhang Q; Zhao H; Zheng F
    Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
    Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
    Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
    Promkan M; Liu G; Patmasiriwat P; Chakrabarty S
    Int J Cancer; 2009 Dec; 125(12):2820-8. PubMed ID: 19551867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
    Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel.
    Togashi K; Okada M; Yamamoto M; Suzuki S; Sanomachi T; Seino S; Yamashita H; Kitanaka C
    Anticancer Res; 2018 Aug; 38(8):4535-4542. PubMed ID: 30061219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small interfering RNA-mediated silencing of heat shock protein 27 (HSP27) Increases chemosensitivity to paclitaxel by increasing production of reactive oxygen species in human ovarian cancer cells (HO8910).
    Song TF; Zhang ZF; Liu L; Yang T; Jiang J; Li P
    J Int Med Res; 2009; 37(5):1375-88. PubMed ID: 19930842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Over-expression of survivin is a factor responsible for differential responses of ovarian cancer cells to S-allylmercaptocysteine (SAMC).
    Wu J; Zhao S; Zhang J; Qu X; Jiang S; Zhong Z; Zhang F; Wong Y; Chen H
    Exp Mol Pathol; 2016 Apr; 100(2):294-302. PubMed ID: 26896649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
    Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
    Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of RhoGDIα induces apoptosis and increases lung cancer cell chemosensitivity to paclitaxel.
    Rong F; Li W; Chen K; Li DM; Duan WM; Feng YZ; Li F; Zhou XW; Fan SJ; Liu Y; Tao M
    Neoplasma; 2012; 59(5):541-50. PubMed ID: 22668020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel.
    Khan Z; Khan N; Varma AK; Tiwari RP; Mouhamad S; Prasad GB; Bisen P
    Curr Cancer Drug Targets; 2010 Nov; 10(7):660-9. PubMed ID: 20578991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
    Shi Y; Zhang J; Liu M; Huang Y; Yin L
    J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.